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RESEARCH
Procalcitonin and lung ultrasonography point-of-care  testing 
to determine antibiotic prescription in patients with lower 
 respiratory tract infection in primary care: pragmatic cluster 
 randomised trial
Loïc Lhopitallier,1 Andreas Kronenberg,2,3 Jean-Yves Meuwly,4 Isabella Locatelli,5  
Yolanda Mueller,6 Nicolas Senn,6 Valérie D’Acremont,5,7,8 Noémie Boillat-Blanco1
ABSTRACT
OBJECTIVE
To assess whether point-of care procalcitonin and 
lung ultrasonography can safely reduce unnecessary 
antibiotic treatment in patients with lower respiratory 
tract infections in primary care.
DESIGN
Three group, pragmatic cluster randomised controlled 
trial from September 2018 to March 2020.
SETTING
60 Swiss general practices.
PARTICIPANTS
One general practitioner per practice was included. 
General practitioners screen all patients with acute 
cough; patients with clinical pneumonia were 
included.
INTERVENTIONS
Randomisation in a 1:1:1 of general practitioners to 
either antibiotics guided by sequential procalcitonin 
and lung ultrasonography point-of-care tests (UltraPro; 
n=152), procalcitonin guided antibiotics (n=195), or 
usual care (n=122).
MAIN OUTCOMES
Primary outcome was proportion of patients in each 
group prescribed an antibiotic by day 28. Secondary 
outcomes included duration of restricted activities 
due to lower respiratory tract infection within 14 days.
RESULTS
60 general practitioners included 469 patients 
(median age 53 years (interquartile range 38-66); 
278 (59%) were female). Probability of antibiotic 
prescription at day 28 was lower in the procalcitonin 
group than in the usual care group (0.40 v 0.70, cluster 
corrected difference −0.26 (95% confidence interval 
−0.41 to −0.10)). No significant difference was seen 
between UltraPro and procalcitonin groups (0.41 v 
0.40, −0.03 (−0.17 to 0.12)). The median number of 
days with restricted activities by day 14 was 4 days in 
the procalcitonin group and 3 days in the usual care 
group (difference 1 day (95% confidence interval −0.23 
to 2.32); hazard ratio 0.75 (95% confidence interval 
0.58 to 0.97)), which did not prove non-inferiority.
CONCLUSIONS
Compared with usual care, point-of-care procalcitonin 
led to a 26% absolute reduction in the probability 
of 28 day antibiotic prescription without affecting 
patients’ safety. Point-of-care lung ultrasonography 
did not further reduce antibiotic prescription, 
although a potential added value cannot be excluded, 




Lower respiratory tract infections are among the most 
common acute reasons for patients to consult general 
practitioners and often lead to inadequate prescription 
of antibiotics.1-4 Despite most patients presenting 
to their general practitioners with lower respiratory 
tract infections receive an antibiotic prescription, only 
5-12% of them have community acquired pneumonia, 
which requires antibiotic treatment.5 The absence of 
specific signs and symptoms for community acquired 
pneumonia makes identification of these patients 
challenging.6 The presence of a new infiltrate on 
chest radiograph confirms a definitive diagnosis of 
pneumonia.6 7 However, chest radiograph is not always 
available in the outpatient setting,8 9 exposes patients 
to radiation, and has limited diagnostic accuracy.10
Procalcitonin is a biomarker with a high sensitivity 
(92%, 95% confidence interval 86% to 95%) in 
differentiating bacterial infections from viral infections 
in acute respiratory infections.11 Measurement of this 
inflammatory host biomarker is now available as a 
point-of-care test, making its use relevant to primary 
care. Several trials evaluated the use of laboratory 
based procalcitonin to guide antibiotic prescription in 
patients with acute respiratory infections in primary 
care and in emergency departments.8 12-14 Inclusion 
of patients for whom antibiotics are not recommended 
and high differences in adherence to procalcitonin 
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Inappropriate antibiotic prescription is common in primary care for patients with 
lower respiratory tract infections
Procalcitonin testing can safely reduce antibiotic prescription in patients with 
lower respiratory tract infections in emergency departments
Lung ultrasonography is an effective tool for detecting lung consolidation
WHAT THIS STUDY ADDS
Use of point-of-care procalcitonin led to a reduction in antibiotic prescription 
rates at 28 days in patients with a lower respiratory tract infection in primary 
care; it also led to a reduction in in the use of chest radiographs by general 
practitioners
Use of point-of-care lung ultrasonography in patients with a procalcitonin level of 
0.25 μg/L or higher did not further reduce antibiotic prescription
Reduction of antibiotic prescription did not affect patient’s clinical outcomes and 
satisfaction
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guidance led to conflicting results. No evidence from 
pragmatic trials is available on the impact of point-
of-care procalcitonin to guide antibiotic prescription 
in patients with lower respiratory tract infections in 
primary care. Point-of-care lung ultrasonography 
is effective in detecting lung consolidation for the 
diagnosis of community acquired pneumonia.10 15 16 Its 
high specificity (95%, 95% confidence interval 83% to 
99%)15 could compensate for the limited specificity of 
procalcitonin (73%, 42% to 91%), which is particularly 
important in a setting with a high rate of viral infection 
such as general practices.11 17 The availability of 
portable and affordable machines together with short 
training courses makes ultrasonography suitable for 
primary care. No evidence from randomised controlled 
trials is available on the impact of lung ultrasonography 
on antibiotic prescription.
We conducted a multicentre trial to test (1) whether 
point-of-care procalcitonin guided treatment would 
decrease unnecessary antibiotic prescriptions 
compared with usual care, and (2) whether an 
intervention combining procalcitonin with lung 
ultrasonography would further reduce prescription 
of antibiotics compared with procalcitonin only in 
patients consulting general practitioners for a lower 
respiratory tract infection.
Methods
Trial design and setting
This three group, open label, pragmatic, cluster 
randomised superiority trial was conducted from 
September 2018 to March 2020, in accordance with 
a previously published protocol.18 We chose a cluster 
design, with randomisation at the general practitioner 
level, to reduce contamination between groups. 
The trial initially recruited patients from 42 general 
practices in western and central-western Switzerland. 
Owing to slow recruitment, 18 additional practices 
included patients from August 2019, bringing the 
total of general practitioners to 60. The Swiss ethics 
committees of cantons Vaud and Bern approved 
the protocol (2017-01246). All study participants 
gave their written consent. An external independent 
monitoring board supervised the trial.
Randomisation, participants, and trial interventions
We randomly allocated practices to a study group with 
a 1:1:1 ratio with variable block sizes, according to a 
computer generated randomisation list. 
General practitioners were eligible if they did not 
use point-of-care procalcitonin nor point-of-care lung 
ultrasonography for the diagnosis of pneumonia. 
General practitioners screened for inclusion all 
consecutive patients aged 18 or older presenting 
with an acute cough (≤21 days). General practitioners 
included patients with clinical pneumonia, defined 
as an acute cough and at least one of the following 
signs or symptoms: history of fever of more than 4 
days, dyspnoea, tachnypnoea (>22 cycles/min), or 
abnormal focal lung auscultation.2 Exclusion criteria 
are available in the supplementary material (table S1).
The study team trained general practitioners 
and medical assistants before participation in the 
study. Details of the curriculum are available in the 
supplementary material (section 3).
UltraPro group
The UltraPro algorithm combines the results of 
point-of-care procalcitonin with point-of-care lung 
ultrasonography in a sequential manner to guide 
antibiotic prescription. The medical assistant measured 
procalcitonin, using the portable BRAHMS PCT direct 
point-of-care test (Thermo-Fischer Scientific). This 
immunoassay has a measuring range of 0.22-10 μg/L 
and provides a quantitative result in 20 minutes using 
20 μL of venous whole blood.
For any elevated concentrations of procalcitonin 
(≥0.25 μg/L), general practitioners did lung 
ultrasonography using a portable L12-4 convex 
transducer (Philips Lumify). The algorithm 
recommended prescribing antibiotics only in the 
presence of both an elevated procalcitonin and a lung 
consolidation (fig S1).
Procalcitonin group
The algorithm recommended prescribing antibiotics 
only in the presence of an elevated procalcitonin 
(≥0.25 μg/L) (fig S1). In all groups, antibiotic choice, 
dose, and duration were left to the discretion of the 
general practitioners who could also order further 
diagnostic tests.
Trial procedures
General practitioners recorded baseline data on 
patient’s clinical presentation, comorbidities, and 
diagnostic procedures using an electronic case report 
form (research electronic data capture).19 Members 
of the study team, blinded to study group, conducted 
standardised phone interviews of all participants 
on days 7 and 28. Participants were asked to fill 
a previously validated daily symptom diary until 
resolution of symptoms or day 28.20 Additional 
details on the symptom diary are provided in the 
supplementary material (section 5). In case of follow-
up visits, general practitioners managed their patients 
according to their usual practice.
Outcome measures
The primary outcome was the proportion of patients 
in each group prescribed an antibiotic by day 28. 
Secondary outcomes were antibiotic prescription 
at day 0 and by day 7, clinical failure by day 7 
(defined as admission to hospital, death, or absence 
of improvement of fever and/or dyspnoea), severe 
adverse outcome by day 28 (defined as admission to 
hospital or death), duration of restricted activities 
due to the lower respiratory tract infection within 14 
days, duration of the lower respiratory tract infection 
episode (based on a total symptoms score reported 
by patients) within 28 days, antibiotics side effects, 
chest radiograph at the initial consultation, follow-up 
medical visits for the episode of lower respiratory tract 
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infection by day 28, and patient reported satisfaction 
with clinical management at day 7.
Statistical analyses
For the sample size calculation, we assumed 60% of 
patients would receive antibiotics with usual care.21 
We calculated the sample size to assess an absolute 
difference in antibiotic prescriptions of at least 15% 
between the usual care group and the procalcitonin 
group (decrease from 60% to 45%) and at least 15% 
between the procalcitonin group and the UltraPro 
group (decrease from 45% to 30%) (fig S2). An expert 
panel agreed on a minimal 15% antibiotic reduction 
as the lower limit to justify eventual implementation of 
these interventions.
A study sample of 60 general practitioners and a 
mean of 10 patients per general practitioners (200 
patients per group for a total of 600 participants) gives 
a power of 80% to detect the expected difference in 
antibiotic prescription with 5% level of significance, 
when adjusting for clustering at practice level 
(intracluster correlation coefficient 0.06). Additional 
details on the sample size calculation and the achieved 
power are provided in the supplementary material 
(section 6).
For the intention-to-treat analysis, all participants 
were included. Those participants lost to telephone 
follow-up were considered as having received 
antibiotics, had a clinical failure, and had a serious 
adverse outcome. We conducted sensitivity analyses to 
assess robustness to missing data, assuming missing 
outcome data as (1) “no antibiotics prescribed,” 
(2) “same as day 0,” or (3) “imputed outcome,” 
and further tested the robustness of the model by 
introducing patient level covariates (table S3). For 
the per protocol analysis, we excluded patients whose 
general practitioners did not follow the algorithm 
recommendation or who did not complete telephone 
follow-up by 28 days. For the descriptive statistical 
analysis, we analysed proportions of categorical 
variables using χ2 goodness of fit test; we used the 
Student t test for normally distributed variables or 
Mann-Whitney-Wilcoxon test for continuous variables 
with a skewed distribution. These tests did not account 
for clustering.
The primary analysis was a logistic regression 
corrected for variation at general practitioner level 
(generalised linear mixed effect model) to estimate 
the difference in the proportion of patients prescribed 
an antibiotic by day 28 as well as the odds ratio 
of antibiotic prescription between two groups. We 
compared binary secondary outcomes using logistic 
mixed effect regression. We compared safety outcomes 
(censored episode duration and censored duration of 
restricted activities) using hazard ratios derived from 
a frailty Cox model, and median difference estimated 
by Kaplan-Meier.
Patient and public involvement
Patients or the public were not involved in the design 
or conduct of this study. During the phone interviews 
on day 7, we assessed patient satisfaction regarding 
the consultation overall, the diagnosis, the prescribed 
treatment, and the amount of time spent with the 
general practitioner, which includes the time required 
to participate in research. These satisfaction outcomes 
were assessed using subquestions from the Visit-
Specific Satisfaction Instrument, previously validated 
for use in French.22
Results
Participants
From 6 September 2018, 60 general practitioners 
screened 3612 patients, of whom 469 were included in 
the trial (UltraPro, 152/1325 (11.5%); procalcitonin, 
195/1189 (16.4%); usual care, 122/1098 (11.1%)), 
435 participants (93%) had complete phone follow-up 
(fig 1 and fig S3). Because of the SARS-CoV-2 outbreak, 
we stopped the trial prematurely on 10 March 2020 
without knowledge of the results. Owing to logistical 
impediments, we did not plan to restart recruitment 
at a later date. The characteristics of the general 
practitioners and the participants were similar across 
the groups (table 1). Median age of the participants 
was 53 years (interquartile range 38-66) and 278 
(59%) participants were female. We saw no significant 
differences in baseline characteristics, apart from 
chronic obstructive pulmonary disease (P=0.02), 
sputum production (P=0.007), fever (P=0.005), 
dyspnoea (P=0.04), chest pain (P<0.001), respiratory 
rate (P=0.02), and CRB-65 score (P=0.02).
Intervention
All patients assigned to both intervention groups 
received the allocated intervention. Nine patients 
(6%) in the UltraPro group had a procalcitonin 
concentration ≥0.25 µg/L, and therefore a lung 
ultrasonography was performed. General practitioners 
identified a lung infiltrate in six (67%) patients. 
Median duration of the lung ultrasonography was 15 
minutes (interquartile range 15-20). Nineteen patients 
(10%) in the procalcitonin group had a procalcitonin 
concentration ≥0.25 µg/L. General practitioners did 
not use procalcitonin and lung ultrasonography in 
the usual care group. General practitioners adhered 
to the recommendation of the algorithm on antibiotic 
prescription in 320 patients (92%). They deviated in 
15 patients (8%) in the procalcitonin group and in 12 
patients (8%) in the UltraPro group.
Primary outcome
Of 469 patients included in the intention-to-
treat analysis of the primary outcome, 408 (87%) 
contributed to the per protocol analysis (fig 1 and 
table S2). Compared with the usual care group, 
the probability of antibiotic prescription by day 28 
was lower in the procalcitonin group (0.40 v 0.70, 
cluster corrected difference −0.26 (95% confidence 
interval −0.41 to −0.10); fig 2 and table 2). We saw 
no significant difference in antibiotic prescription by 
day 28 between the UltraPro group and procalcitonin 
groups (0.41 v 0.40, −0.03 (−0.17 to 0.12)). Compared 
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with the usual care group, the odds ratio of antibiotic 
prescription by day 28 was 0.29 (95% confidence 
interval 0.13 to 0.65; intracluster coefficient 0.150) in 
the procalcitonin group (table 2). Compared with the 
procalcitonin group, the odds ratio of 28 day antibiotic 
prescription was 0.89 (95% 0.43 to 1.67; 0.096) in the 
UltraPro group (table 2).
These findings were consistent across sensitivity 
analyses, in the per protocol population and when 
adjusting the model for patient level confounding 
factors (table S3). However, we observed wide 
confidence intervals for the comparison between 
groups. Details of antibiotic prescriptions at day 0 are 
provided in the supplementary material (table S4).
Secondary outcomes
The probability of antibiotic prescription at day 0 was 
lower in the procalcitonin group than in the usual care 
group (0.18 v 0.57; cluster corrected difference −0.30 
(95% confidence interval −0.48 to −0.14); fig 2 and 
table 2). We saw no significant difference between the 
UltraPro and procalcitonin groups (0.16 v 0.18, −0.02 
(−0.16 to 0.12)).
The probability of antibiotic prescription by day 7 
was lower in the procalcitonin group than in the usual 
care group (0.30 v 0.61; cluster corrected difference 
−0.24 (95% confidence interval −0.41 to −0.08); fig 2 
and table 2). We saw no significant difference between 
the UltraPro and procalcitonin groups (0.31 v 0.30, 
−0.01 (−0.15 to 0.12)).
The characteristics of patients having received 
an antibiotic between days 1 and 28 despite a 
procalcitonin level less than 0.25 µg/L at day 0 are 
provided in the supplementary material (tables S5 
and S6). The only factors associated with antibiotic 
prescription were the presence of chest pain at day 0 
and a longer duration of symptoms. Nine (2%) patients 
were admitted to hospital by day 28. No deaths were 
Randomised practices
Did not meet inclusion criteria 
Suspicion of non-infective disorder
Time constraints
Cannot provide consent
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Recent COPD exacerbation













Patients screened for inclusion
Practices allocated to usual care group
737




Patients screened for inclusion
1189
Patients screened for inclusion
1325
Patients included in intention-to-treat analysis
(median per GP=6, range=1-20)
60
20
Practices with recruited patients
17
Practices allocated to procalcitonin group
20
Practices with recruited patients
19
Practices allocated to UltraPro group
20
Practices with recruited patients
19
38
Did not meet inclusion criteria 
Suspicion of non-infective disorder
Time constraints
Cannot provide consent
Already received antibiotics for this
  episode
Recent COPD exacerbation
















Did not meet inclusion criteria 
Suspicion of non-infective disorder
Time constraints
Cannot provide consent
Already received antibiotics for this
  episode
Recent COPD exacerbation













Patients included in per protocol analysis
131
Patients included in intention-to-treat analysis
(median per GP=10.5, range=1-22)
195
Patients included in intention-to-treat analysis
(median per GP=6, range=1-15)
122




Deviation from algorithm suggestion
No phone follow-up at day 28
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114
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8
Fig 1 | Consort flowchart of trial participants. COPD=chronic obstructive pulmonary disease
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reported. Although confidence intervals were wide, we 
saw no significant differences in clinical failure by day 
7 and in serious adverse outcomes by day 28 between 
the procalcitonin and usual care groups or between 
the Ultrapro and procalcitonin groups (table 2 and 
table S8). Table S7 details the various elements of the 
clinical failure composite outcome by day 7.
We saw no significant differences in antibiotic side 
effects within 28 days between the procalcitonin 
and usual care groups or between the UltraPro 
and procalcitonin groups (table 2). Patients in the 
procalcitonin group were less likely than those in the 
usual care group to have had a chest radiograph at 
day 0 (0.21 v 0.55; cluster corrected difference −0.33 
(95% confidence interval −0.51 to −0.14); table 2 and 
fig S4). We saw no significant difference between the 
UltraPro group and the procalcitonin group (0.18 v 
0.21; −0.11 (−0.26 to 0.05)). For patients receiving 
at least one follow-up visit, we saw no significant 
differences between the procalcitonin and usual care 
groups or between the UltraPro and procalcitonin 
groups (table 2).
The median number of days with restricted activities 
due to lower respiratory tract infection by day 14 was 
4 days in the procalcitonin group and 3 days in the 
usual care group. The 95% confidence interval around 
the median difference (−0.23 to 2.32) included the 
prespecified margin (1 day), therefore non-inferiority 
was not proven (hazard ratio 0.75 (95% confidence 
interval 0.58 to 0.97; table 3). We saw no difference in 
the number of days with restricted activities by day 14 
between the UltraPro and procalcitonin groups (4 v 4 
days; median difference 0.0 (95% confidence interval 
−1.48 to 1.43); hazard ratio 1.01 (0.80 to 1.29)). The 
median duration of the episode by day 28 was 8 days 
in the procalcitonin group and 7 days in the usual 
care group (median difference 1.0 (−0.39 to 2.43), 
hazard ratio 0.81 (0.62 to 1.04)). We saw no difference 
in the duration of the episode by day 28 between the 
UltraPro and procalcitonin groups (median difference 
0.0 (−1.68 to 1.74); hazard ratio 0.97 (0.76 to 1.24)).
We saw no statistical difference in the prescription 
of C reactive protein and white blood count at day 
0 between study groups (table S9). Furthermore, 
no significant differences were seen in patient 
reported satisfaction outcomes among the UltraPro, 
procalcitonin, and usual care groups (table S10).
Discussion
Principal findings
Procalcitonin point-of-care guided treatment led 
to a statistically significant reduction of antibiotic 
prescription by day 28 of presentation compared with 
usual care in low risk patients with clinical evidence 
of community acquired pneumonia in primary 
care, with an absolute difference of 26%, without 
affecting patients’ safety or patients’ satisfaction. 
Point-of-care lung ultrasonography in patients 
with elevated procalcitonin level, according to the 
UltraPro algorithm, did not further reduce antibiotic 
prescription within 28 days when compared with 
treatment guided by procalcitonin only, suggesting no 
added benefit from its use in our algorithm. However, 
the wide confidence interval around this difference 
cannot exclude a clinically significant effect. 
Because general practitioners had to perform 
lung ultrasonography only for instances of elevated 
procalcitonin, few ultrasonographies were conducted, 
which limited the possibility to show additional 
reduction in antibiotic prescription. The absence of 
significant differences between groups in clinical 
failure, serious adverse outcomes, symptom duration, 
and follow-up consultation rates suggests that 
prescribing fewer antibiotics does not affect safety. 
However, the wide confidence intervals observed for 
Table 1 | Baseline characteristics of participants, by study group. Data are number (%) 
unless stated otherwise
Trial group
UltraPro Procalcitonin Usual care
General practitioners
No 20 20 20
Female 8 (40) 8 (40) 9 (45)
Practice in French speaking region 19 (95) 15 (75) 16 (80)
>10 years’ practice 8 (40) 11 (55) 10 (50)
>5 general practitioners in practice 3 (15) 6 (30) 3 (15)
Practice in urban setting 15 (75) 13 (65) 13 (65)
Radiology available in practice 10 (50) 12 (60) 13 (65)
Ultrasonography available in practice 3 (15) 6 (30) 7 (35)
Participants
No 152 195 122
Demographic characteristics and comorbidities
 Female 87 (57) 126 (65) 65 (53)
 Age (years; mean (SD)) 52 (17.0) 53 (18.0) 50 (18.0)
 Active smoker 26 (17) 44 (23) 31 (25)
 Alcohol misuse 4 (3) 2 (1) 5 (4)
 Heart failure 1 (1) 3 (2) 0
 Diabetes 4 (3) 13 (7) 4 (3)
 Chronic obstructive pulmonary disease 3 (2) 18 (9) 9 (7)
 Asthma 20 (13) 37 (19) 13 (11)
 Active malignancy 1 (1) 4 (2) 0
Presenting complaints
 Duration of cough (days; median (IQR)) 6 (3-9) 7 (4-11) 6 (4-10)
 Sputum production 92 (61) 148 (76) 82 (68)
 History of fever 106 (70) 117 (60) 94 (77)
 Duration of fever (days; median (IQR)) 3 (2-5) 4 (2-5) 4 (3-5)
 History of dyspnoea 108 (71) 126 (65) 68 (56)
 History of chest pain 69 (45) 96 (49) 32 (26)
Clinical presentation
 Systolic blood pressure (mm Hg; median (SD)) 128 (17) 130 (19) 130 (20)
 Heart rate (beats/min; mean (SD)) 85 (14) 84 (14) 86 (14)
 Respiratory rate (cycles/min; mean (SD)) 19 (4) 18 (5) 18 (5)
 Temperature (°C; mean (SD)) 37.0 (0.8) 37.0 (0.8) 37.0 (0.8)
 SpO2 (median (IQR)) 97 (95-98) 97 (94-98) 97 (95-98)
 Abnormal auscultation 60 (39) 96 (49) 64 (52)
CRB-65 score (No (%))*
 0 114 (75) 127 (65) 86 (70)
 1 37 (24) 65 (33) 30 (25)
 2 0 1 (1) 4 (3)
 Unknown 1 (1) 2 (1) 2 (2)
DS-CRB-65 score (No (%))*
 0 87 (58) 112 (56) 62 (51)
 1 28 (18) 50 (26) 27 (22)
 2 3 (2) 19 (10) 5 (4)
 3 0 1 (1) 2 (2)
 Unknown 34 (22) 13 (7) 26 (21)
COPD=chronic obstructive pulmonary disease; SD=standard deviation; IQR=interquartile range. 
*CRB-65 and DS-CRB-65 scores predict the severity of pneumonia and are calculated according to Kolditz et al.23
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some of these secondary outcomes do not allow us to 
exclude large differences. The increase on 1 day in the 
restricted activity duration between the intervention 
and usual care groups suggests an effect on wellbeing, 
with the upper boundary of the 95% confidence 
interval above our prespecified non-inferiority margin. 
However, the confidence interval was narrow and 
the estimated difference remained low and likely 
to be not clinically relevant. A reduction in the use 
of chest radiographs in both intervention groups 
compared with the usual care group suggested that the 
intervention could also limit patient irradiation.
Strengths and limitations
We chose a cluster randomised trial design to ensure 
the feasibility of the trial from a logistical aspect, which 



























Day 0 Day 7 Day 28
Usual care (n=122) Procalcitonin (n=195) UltraPro (n=152)
Fig 2 | Probability (%) of antibiotic prescription by days 0, 7, and 28 according to study 
group (usual care, procalcitonin, and UltraPro (sequential procalcitonin and lung 
ultrasonography point-of-care tests))
Table 2 | Effect of procalcitonin versus usual care, and of UltraPro versus procalcitonin on primary outcome and binary 
secondary outcomes in the intention-to-treat population. P values pertain to odds ratios





Group comparison (procalcitonin v usual care; UltraPro v procalcitonin)
Estimated difference 
corrected for cluster 
size (95% CI)
Unadjusted odds ratio 




Antibiotic prescription by day 28
 Usual care 122 86 (70) — — — —
 Procalcitonin 195 78 (40) −0.26 (−0.41 to −0.10) 0.29 (0.13 to 0.65) 0.001 0.150
 Procalcitonin 195 78 (40) — — — —
 UltraPro 152 62 (41) −0.03 (−0.17 to 0.12) 0.89 (0.43 to 1.67) 0.71 0.096
Secondary outcome measures
Antibiotic prescription at day 0
 Usual care 122 69 (57) — — — —
 Procalcitonin 195 35 (18) −0.30 (−0.48 to −0.14) 0.17 (0.05 to 0.50) 0.001 0.312
 Procalcitonin 195 35 (18) — — — —
 UltraPro 152 25 (16) −0.02 (-0.16 to 0.12) 0.85 (0.38 to 1.89) 0.68 0.132
Antibiotic prescription by day 7
 Usual care 122 75 (61) — — — —
 Procalcitonin 195 58 (30) −0.24 (−0.41 to −0.08) 0.29 (0.12 to 0.72) 0.004 0.212
 Procalcitonin 195 58 (30) — — — —
 UltraPro 152 47 (31) −0.01 (−0.15 to 0.12) 0.94 (0.44 to 1.83) 0.86 0.101
Clinical failure by day 7
 Usual care 122 52 (43) — — — —
 Procalcitonin 195 84 (43) 0.01 (−0.14 to 0.15) 1.04 (0.51 to 2.02) 0.90 0.097
 Procalcitonin 195 84 (43) — — — —
 UltraPro 152 67 (44) 0.02 (−0.12 to 0.15) 1.08 (0.61 to 2.04) 0.80 0.068
Serious adverse outcome by day 28
 Usual care 122 10 (8) — — — —
 Procalcitonin 195 20 (10) 0.03 (−0.06 to 0.10) 1.40 (0.56 to 4.25) 0.49 0.097
 Procalcitonin 195 20 (10) — — — —
 UltraPro 152 11 (7) −0.03 (−0.09 to 0.03) 0.68 (0.30 to 1.44) 0.32 0.176
Any side effects from antibiotics by day 28
 Usual care 122 38 (31) — — — —
 Procalcitonin 195 41 (21) −0.10 (−0.21 to 0.02) 0.60 (0.31 to 1.16) 0.11 0.061
 Procalcitonin 195 41 (21) — — — —
 UltraPro 152 30 (20) −0.02 (−0.11 to 0.08) 0.90 (0.48 to 1.68) 0.73 0.051
Chest radiograph (performed at day 0)
 Usual care 122 67 (55) — — — —
 Procalcitonin 195 40 (21) −0.33 (−0.51 to −0.14) 0.13 (0.04 to 0.44) <0.001 0.390
 Procalcitonin 195 40 (21) — — — —
 UltraPro 152 27 (18) −0.11 (−0.26 to 0.05) 0.32 (0.06 to 1.66) 0.18 0.509
At least one follow-up visit (days 1 to 28)
 Usual care 122 33 (27) — — — —
 Procalcitonin 195 53 (27) 0.01 (−0.13 to 0.16) 1.10 (0.49 to 2.56) 0.81 0.152
 Procalcitonin 195 53 (27) — — — —
 UltraPro 152 43 (28) 0.00 (−0.10 to 0.11) 1.01 (0.6 to 1.7) 0.96 0.021
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between study arms. Contamination is important in 
trials carried out in general practices where individual 
patients are treated by the same physician, which 
might dilute or even negate the intervention impact. 
Indeed, the interventions target patient management 
at the general practitioner level. Although the cluster 
design introduces the possibility of recruitment bias 
after randomisation (because a different number of 
patients and patients with different characteristics 
might be included after the intervention has been 
allocated24), it is the only study design that avoids 
contamination across groups that would arise from 
using randomisation at the individual level. 
No substantial differences were seen in the 
characteristics of general practitioners. However, 
we observed a different screening and recruitment 
rate between study arms with a lower rate in the 
usual care group, as well as some differences in the 
baseline characteristics of participants suggesting 
the presence of a recruitment bias. The prevalence of 
chronic obstructive pulmonary disease and sputum 
production as well as low severity disease (CRB-65 
severity score of 0) were lower in the UltraPro group. 
Prevalence of anamnestic fever was higher and of chest 
pain was lower in the usual care group. To account for 
these differences, we included potentials confounders 
(relevant patient level covariates) in a sensitivity 
analysis of the statistical model. Furthermore, to 
minimise selection bias, general practitioners screened 
consecutive patients attending care for a cough and 
included patients based on stringent, reproducible, 
and objective criteria. They included only patients 
with clinical pneumonia who, according to guidelines 
and not to physician opinion, might benefit from 
antibiotics.2 Although our study had a recruitment 
bias, our findings were robust and the differences in 
the baseline characteristics of participants have little 
relevance from a clinical viewpoint, suggesting its 
effect on our results was minor.
We observed a low proportion of included patients 
among all screened patients, raising the question of 
the generalisability of our results. This low proportion 
is due to our stringent inclusion criteria of clinical 
pneumonia, which excluded patients who do not need 
antibiotics based on clinical criteria alone according to 
guidelines. Only 22% (588/2674) of excluded patients 
were prescribed an antibiotic at the initial consultation, 
while this proportion rose to 57% (69/122) in the 
usual care group at day 0, suggesting that we selected 
the appropriate target population.
Although we conducted a pragmatic study, 
general practitioners adhered to the algorithm’s 
recommendations at inclusion at a high rate (92%; 
320/347), suggesting that they integrated the 
intervention in their practice even with minimal 
training.
Our primary outcome was antibiotic prescription 
by day 28 rather than antibiotic prescription at day 
0, which shows that the effect of our intervention 
persisted over time. However, antibiotic prescription 
more than doubled in the intervention groups between 
days 1 and 28. Baseline characteristics of patients, 
including clinical severity, and of general practitioners 
were similar between patients who did and did not 
receive antibiotics during follow-up despite a low 
procalcitonin value at baseline. Patients who received 
antibiotics during follow-up presented a longer 
duration of symptoms, suggesting that antibiotic 
prescription during follow-up was not related to 
patients’ clinical severity, but rather to persisting 
symptoms. These data highlight the importance to 
inform patients and providers about the expected 
duration of an acute respiratory tract infection. 
Additional interventions during follow-up or improved 
information at first consultation might also further 
reduce antibiotic prescription.
This clinical trial evaluated lung ultrasonography for 
the management of lower respiratory tract infections, 
and we did not show any benefit from its use in low risk 
patients with clinical community acquired pneumonia 
and procalcitonin values ≥0.25 μg/L. General 
practitioners only performed lung ultrasonography 
in patients with elevated procalcitonin, which saved 
their time while managing the patients, a strategy that 
was considered easier to implement at a larger scale if 
proven successful. However, we only observed elevated 
levels of procalcitonin in 6% (9/152) of patients in the 
UltraPro group, which suggests limited additional room 
for reducing antibiotic prescription using sequential 
tests after procalcitonin use at first consultation. 
Whether lung ultrasonography might be useful as the 
first diagnostic test, in parallel to procalcitonin or in a 
higher risk population with clinical pneumonia, is not 
assessed in this study.
Owing to the first epidemic wave of SARS-CoV-2 
in Switzerland, we had to stop the trial prematurely 
because we did not consider it feasible to continue 
recruiting participants under these exceptional 
circumstances. However, we did not identify any SARS-
CoV-2 infection in trial participants.25 We, therefore, 
did not reach our target sample size. Nevertheless, 
with over than 100 patients in each group, the 
comparison between procalcitonin and usual care 
yielded significant results. Owing to the nature of the 
Table 3 | Effect of study group comparisons (procalcitonin v usual care; UltraPro v 
procalcitonin) on censored duration of limited activities due to lower respiratory tract 
infection by day 14 and censored duration of episode by day 28. Analysis accounted for 
the cluster effect via a frailty term. No evidence of non-proportionality was detected by 





Group comparison (procalcitonin v usual care, 
and UltraPro v procalcitonin)
Duration difference 
(days; 95% CI)
Hazard ratio  
(95% CI)
Duration of limited activities by day 14
Usual care 102 3 — —
Procalcitonin 159 4 1.0 (−0.23 to 2.32) 0.75 (0.58 to 0.97)
Procalcitonin 159 4 — —
UltraPro 129 4 0.0 (−1.48 to 1.43) 1.01 (0.80 to 1.29)
Duration of symptoms by day 28
Usual care 102 7 — —
Procalcitonin 159 8 1.0 (−0.39 to 2.43) 0.81 (0.62 to 1.04)
Procalcitonin 159 8 — —
UltraPro 129 8 0.0 (−1.68 to 1.74) 0.97 (0.76 to 1.24)
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UltraPro algorithm (lung ultrasonography performed 
only in patients with elevated procalcitonin) and to the 
low prevalence elevated procalcitonin in this setting, 
we do not expect that the UltraPro algorithm could 
reduce antibiotic prescription sufficiently to have a 
public health impact, compared with procalcitonin 
only, even with a much higher sample size. However, 
with the wide confidence intervals when comparing 
the UltraPro group to the procalcitonin group, we 
cannot formally exclude a potential added value of this 
intervention.
General practitioners’ participation on a voluntary 
basis led to a possible inclusion bias. Indeed, we 
expected these general practitioners to have lower 
rates of inadequate antibiotic prescription. Therefore, 
we could have underestimated the impact of our 
intervention. Over-prescription of antibiotics in 
primary care is a concern in Switzerland, albeit a lesser 
one than in other European countries. The daily defined 
dose per 1000 inhabitants per day in Switzerland 
is 9.1 versus 18.4 in countries participating in the 
European Surveillance of Antimicrobial Consumption 
Network surveillance study.26 We hypothesise that 
if the intervention is efficacious in a setting with low 
prescription rates, its impact would probably be robust 
in settings with high prescription rates.
Owing to the pragmatic nature of the study and to 
the intervention, we conducted an open label study. 
This design could modify practitioners’ or patients’ 
behaviour—for example, the number of follow-up 
consultations when antibiotics were not prescribed 
or a subjective slower improvement of symptoms in 
patients who did not receive any antibiotics. However, 
this open label design better mimics real world settings.
Comparison with other studies
Although procalcitonin guided treatment led to a 
reduction of antibiotic prescription for acute respiratory 
infections in two randomised control trials in primary 
care, few participants had a lower respiratory tract 
infection preventing recommendation in this patient 
group.8 14 Furthermore, inclusion criteria were non-
reproducible, which makes application of study 
findings difficult in another setting. Two randomised 
controlled trials tested procalcitonin guided treatment 
in patients with lower respiratory tract infections in 
the emergency department, and showed conflicting 
results on antibiotic prescription, mainly due to 
physician’s adherence to the guidance and to the 
patient population.12 13
Policy implications
The evidence from our trial expands the knowledge 
on the impact of procalcitonin guided treatment in 
patients with lower respiratory tract infections to 
primary care. Procalcitonin is now available at the point 
of care, which makes the implementation of its use in 
primary care scalable. The pragmatic design of our 
study also supports the feasibility of implementation. 
However, further analyses regarding the acceptability 
of the intervention by general practitioners and cost 
effectiveness ratio of the intervention are warranted 
to consider large scale implementation. The external 
validation of our findings in settings with different 
epidemiology or during outbreaks, such as SARS-
CoV-2, needs confirmation.
Conclusions
The evidence from this trial suggests that using point-
of-care procalcitonin for patients with lower respiratory 
tract infection in primary care reduces antibiotic use 
without prejudicing patients’ clinical recovery and 
satisfaction. However, we could not show any added 
benefit from the use of lung ultrasonography to 
manage these patients, when used for those with an 
elevated procalcitonin level.
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